V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10007111 | 10004954 | 1.68 | 70 | Palliative (P) | 2016-12-10 | 2016-12-23 | CRIZOTINIB | 2 | N | 10503009 | PAZOPANIB |
| 10007112 | 10004956 | 1.65 | 63 | Palliative (P) | 2017-01-04 | 2017-01-06 | Hydroxycarbamide | N | N | 10503151 | PALBOCICLIB |
| 10007113 | 10004957 | 1.7 | 73 | Neo-adjuvant (N) | 2014-12-24 | 2014-12-27 | Capecitabine (14 day) + Irinotecan | N | Y | 10503453 | PMITCEBO |
| 10007114 | 10004958 | 1.76 | null | null | 2017-11-17 | 2018-01-01 | PCV | N | N | 10504071 | CHLORAMBUCIL + RITUXIMAB |
| 10007115 | 10004960 | 1.67 | 52 | Curative (C) | 2017-02-08 | 2017-02-09 | PERTUZUMAB + TRASTUZUMAB | 02 | N | 10504185 | CISPLATIN + FLUOROURACIL |
| 10007116 | 10007494 | 1.66 | 60.1 | Neo-adjuvant (N) | 2017-01-01 | 2017-01-05 | Bortezomib + MELPHALAN | N | N | 10504193 | CARBOPLATIN + PACLITAXEL + RT |
| 10007117 | 10004961 | 1.6 | 63.5 | Palliative (P) | 2015-10-09 | 2015-11-08 | IMATINIB | 2 | N | 10504251 | TAC |
| 10007118 | 10004964 | 1.78 | 74.4 | Palliative (P) | 2018-02-09 | 2018-03-10 | Cisplatin + Pemetrexed | N | N | 10504301 | TEMOZOLOMIDE + RT |
| 10007119 | 10004966 | 1.8 | 78 | Palliative (P) | 2017-01-14 | 2017-01-26 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | 10504311 | MELPHALAN |
| 10007120 | 10004966 | 1.55 | 48 | Palliative (P) | 2017-12-12 | 2017-12-13 | Vinblastine | 2 | N | 10504311 | CHLORAMBUCIL + RITUXIMAB |
| 10007121 | 10007498 | 1.77 | 73 | Palliative (P) | 2018-03-08 | 2018-04-07 | ECX | 02 | N | 10504440 | TEMOZOLOMIDE + RT |
| 10007122 | 10004969 | 1.57 | 69 | Palliative (P) | 2017-11-03 | 2017-11-11 | FEC 100 + DOCETAXEL + TRASTUZUMAB | 02 | N | 10504736 | CHLORAMBUCIL + RITUXIMAB |
| 10007123 | 10004971 | 0 | 67.4 | Palliative (P) | 2014-11-12 | 2015-02-26 | Cetuximab+Irinotecan (Cyc2 onwards) | 02 | N | 10504977 | FLUOROURACIL + MITOMYCIN + RT |
| 10007124 | 10004972 | 1.79 | 84 | Palliative (P) | 2018-11-30 | 2018-12-03 | THALIDOMIDE | N | N | 10505004 | VEMURAFENIB |
| 10007125 | 10007499 | null | 70 | Palliative (P) | 2016-03-16 | 2016-03-16 | IPILIMUMAB + NIVOLUMAB | N | N | 10505104 | NIVOLUMAB |
| 10007126 | 10007499 | null | null | Palliative (P) | 2017-09-23 | 2017-09-24 | Folfirinox | N | null | 10505104 | CAV |
| 10007127 | 10004973 | 1.8 | 84 | Palliative (P) | 2017-01-15 | 2017-01-17 | PMitCEBO-R | N | N | 10505533 | CHOP |
| 10007128 | 10004976 | 1.78 | 65 | Palliative (P) | 2018-06-02 | 2018-06-07 | MPV (cycle 1-4) | N | N | 10505550 | OXALIPLATIN |
| 10007129 | 10004977 | null | null | Palliative (P) | 2017-06-29 | 2017-06-29 | Bortezomib +/- Dexamethasone | N | N | 10505550 | GEFITINIB |
| 10007130 | 10004978 | 1.58 | 80.3 | Palliative (P) | 2015-04-04 | 2015-04-05 | BORTEZOMIB + THALIDOMIDE | 02 | N | 10505645 | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN |
| 10007131 | 10004978 | 1.66 | 77.8 | Palliative (P) | 2015-02-02 | 2015-02-14 | Gemcitabine + Capecitabine | N | N | 10505645 | PERTUZUMAB + TRASTUZUMAB |
| 10007132 | 10004979 | 1.7 | 85.7 | Adjuvant (A) | 2019-03-05 | 2019-04-04 | CMF IV (28 day) | 1 | Y | 10505773 | MITOMYCIN INTRAVESICULAR |
| 10007133 | 10004980 | 1.58 | 53.1 | Adjuvant (A) | 2018-11-26 | 2018-12-18 | Cetuximab + Oxaliplatin + MdG Maint | 02 | N | 10505847 | PERTUZUMAB + TRASTUZUMAB |
| 10007134 | 10004982 | 1.7 | 0 | Palliative (P) | 2018-03-07 | 2018-03-11 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 10505847 | FEC + DOCETAXEL + TRASTUZUMAB |
| 10007135 | 10004982 | 1.58 | 80 | Neo-adjuvant (N) | 2017-05-22 | 2017-05-22 | GEM-P | 2 | N | 10505847 | DABRAFENIB + TRAMETINIB |
| 10007136 | 10004983 | 1.73 | 80.6 | Adjuvant (A) | 2015-04-27 | 2015-04-27 | CABOZANTINIB | 02 | N | 10505988 | GDP |
| 10007137 | 10004983 | 1.75 | 74.3 | Adjuvant (A) | 2017-02-20 | 2017-03-13 | Carboplatin + Liposomal Doxorubicin | 02 | N | 10505988 | CAPECITABINE + IRINOTECAN |
| 10007138 | 10009187 | 1.67 | 68 | null | 2018-06-26 | 2018-06-26 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | 10506179 | EOX |
| 10007139 | 10009256 | 0 | 86 | Adjuvant (A) | 2018-08-17 | 2018-08-30 | FEC | 02 | N | 10506303 | CAPECITABINE + GEMCITABINE |
| 10007140 | 10007507 | 1.71 | 62.9 | Not known (9) | 2017-07-28 | 2017-07-28 | GEFITINIB | 02 | N | 10506435 | AFATINIB |
| 10007141 | 10007507 | 1.76 | 80 | Curative (C) | 2015-08-06 | 2015-08-13 | IPILIMUMAB + NIVOLUMAB | 02 | N | 10506435 | FLUOROURACIL + MITOMYCIN + RT |
| 10007142 | 10004985 | 1.69 | 80.9 | Palliative (P) | 2018-02-09 | 2018-02-09 | Carboplatin + Liposomal Doxorubicin | 02 | N | 10506765 | LIPOSOMAL DOXORUBICIN |
| 10007143 | 10004987 | 1.79 | 82.2 | Palliative (P) | 2016-03-20 | 2016-04-08 | FLAG + Idarubicin | 02 | Y | 10506788 | DOCETAXEL + NINTEDANIB |
| 10007144 | 10004988 | 1.68 | 70 | Palliative (P) | 2018-11-23 | 2018-12-15 | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | 02 | N | 10506788 | NIVOLUMAB |
| 10007145 | 10004988 | 0 | 80 | Curative (C) | null | 2015-10-16 | IMATINIB | 2 | null | 10506788 | ETOPOSIDE + RITUXIMAB |
| 10007146 | 10004989 | 0 | 65.7 | Palliative (P) | 2014-02-20 | 2014-03-01 | NIVOLUMAB | N | N | 10506951 | VISMODEGIB |
| 10007147 | 10004989 | 1.63 | null | Disease modification (D) | 2016-06-24 | 2016-09-04 | CETUXIMAB + IRINOTECAN + MDG | N | N | 10506951 | CHLORAMBUCIL |
| 10007148 | 10004989 | 1.7 | null | Palliative (P) | 2019-04-05 | 2019-04-14 | Bortezomib + Panobinostat | 2 | N | 10506951 | EC |
| 10007149 | 10004989 | 1.85 | 82.7 | Palliative (P) | 2015-05-22 | 2015-06-22 | Capecitabine (21days) + Carboplatin | N | N | 10506951 | CETUXIMAB + IRINOTECAN + MDG |
| 10007150 | 10004990 | 1.57 | 60 | Palliative (P) | 2013-10-04 | 2013-10-11 | Chlorambucil | N | N | 10507266 | LOMUSTINE |
| 10007151 | 10004992 | 1.69 | 77.4 | Adjuvant (A) | 2016-05-23 | 2016-06-27 | Melphalan IV High dose | 02 | null | 10507270 | TRIFLURIDINE + TIPIRACIL |
| 10007152 | 10004993 | 1.57 | 62.9 | Palliative (P) | 2018-05-25 | 2018-05-25 | Panitumumab | 02 | N | 10507380 | FEC + DOCETAXEL |
| 10007153 | 10004996 | null | 104.3 | Disease modification (D) | null | 2019-05-16 | Cetuximab 7 day (>Cycle 2) | N | N | 10507458 | CETUXIMAB |
| 10007154 | 10004996 | 1.85 | null | Palliative (P) | 2019-07-25 | 2019-09-20 | CYCLOPHOSPHAMIDE + MITOXANTRONE + RITUXIMAB + VINCRISTINE | N | N | 10507458 | EOX |
| 10007155 | 10004996 | 1.7 | 66 | Adjuvant (A) | 2014-11-18 | 2014-12-23 | MELPHALAN | 02 | null | 10507458 | EC |
| 10007156 | 10004997 | 1.7 | 78 | Curative (C) | 2018-09-22 | 2018-09-28 | Liposomal Doxorubicin 40mg/m2 | 02 | N | 10507600 | CETUXIMAB + IRINOTECAN + MDG |
| 10007157 | 10004997 | 1.75 | 85 | Palliative (P) | 2016-09-02 | 2016-09-02 | BENDAMUSTINE + OFATUMUMAB | 02 | N | 10507600 | POMALIDOMIDE |
| 10007158 | 10004997 | 1.72 | 66.5 | Disease modification (D) | 2018-03-25 | 2018-03-25 | Gefitinib: Cycle 3 only (PAS) | 2 | N | 10507600 | CYCLOPHOSPHAMIDE |
| 10007159 | 10004997 | 1.65 | 74.05 | Palliative (P) | 2017-04-12 | 2017-04-12 | R CODOX-M/ R IVAC | N | N | 10507600 | HCX |
| 10007160 | 10004997 | null | null | Palliative (P) | 2014-09-22 | 2015-04-06 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 2 | null | 10507600 | CISPLATIN + VINORELBINE + RT |